Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study

Journal article

Peer reviewed

A. Poveda, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz, H. Hagberg, C. Lebedinsky, T. V. Parekh and B. J. Monk

Journal of clinical oncology, Vol.28(15_suppl), pp.5012-5012

05/20/2010

Abstract

Abstract only

1 Record Views

Title: Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study
Creators: A. Poveda
S. Tjulandin
B. Kong
M. Roy
S. Chan
E. Filipczyk-Cisarz
H. Hagberg
C. Lebedinsky
T. V. Parekh
B. J. Monk
Publication Details: Journal of clinical oncology, Vol.28(15_suppl), pp.5012-5012
Identifiers: 991005968780302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article